A pilot study of paclitaxel plus pembrolizumab in patients with metastatic HER2-negative breast cancer (PePPy)

被引：0
|
作者：
Tan, Antoinette R.
Chai, S. Jean
Robinson, Myra M.
Hellner, Lane B.
Gavini, Nagajyothi
Sulai, Nanna
Turner, J. David
Atlas, Jennifer
Graham, David L.
Induru, Raghava R.
Kadakia, Kunal C.
Vallabhaneni, Geetha D.
Heeke, Arielle L.
Foureau, David M.
Fisher, Julie G.
机构：
来源：
CANCER RESEARCH | 2022年 / 82卷 / 04期
关键词：
D O I：
10.1158/1538-7445.SABCS21-P2-14-03
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P2-14-03
引用
收藏
页数：3
相关论文
共 50 条
  • [1] Phase II trial of pembrolizumab in combination with nab-paclitaxel in patients with metastatic HER2-negative breast cancer
    Kwa, Maryann J.
    Iwano, Alyssa
    Esteva, Francisco J.
    Novik, Yelena
    Speyer, James L.
    Oratz, Ruth
    Meyers, Marleen Iva
    Axelrod, Deborah M.
    Hogan, Rebecca
    Mendoza, Sandra
    Goldberg, Judith D.
    Muggia, Franco
    Adams, Sylvia
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [2] Nab-paclitaxel plus bevacizumab in heavily pretreated HER2-negative metastatic breast cancer
    Miano, S. T.
    Rossi, G.
    Marsili, S.
    Petrioli, R.
    Pascucci, A.
    Francini, G.
    ANNALS OF ONCOLOGY, 2015, 26 : 22 - 23
  • [3] Phase II study of pembrolizumab plus mifepristone in patients with advanced HER2-negative breast cancer.
    Chen, Nan
    Michaels, Elena
    Saha, Poornima
    Rampurwala, Murtuza M.
    Hahn, Olwen Mary
    Howard, Frederick Matthew
    Fleming, Gini F.
    Karrison, Theodore
    Conzen, Suzanne D.
    Nanda, Rita
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [4] Maintenance Pembrolizumab Therapy in Patients with Metastatic HER2-negative Breast Cancer with Prior Response to Chemotherapy
    Iwase, Toshiaki
    Cohen, Evan N.
    Gao, Hui
    Alexander, Angela
    Kai, Megumi
    Chiv, Vivian
    Wang, Xiaoping
    Krishnamurthy, Savitri
    Liu, Diane
    Shen, Yu
    Kida, Kumiko
    Reuben, Alexandre
    Layman, Rachel M.
    Ramirez, David L.
    Tripathy, Debasish
    Moulder, Stacy L.
    Yam, Clinton
    Valero, Vicente
    Lim, Bora
    Reuben, James M.
    Ueno, Naoto T.
    CLINICAL CANCER RESEARCH, 2024, 30 (11) : 2424 - 2432
  • [5] Paclitaxel plus bevacizumab or paclitaxel as first-line treatment for HER2-negative metastatic breast cancer in a multicenter national observational study
    Delaloge, S.
    Perol, D.
    Courtinard, C.
    Brain, E.
    Asselain, B.
    Bachelot, T.
    Debled, M.
    Dieras, V.
    Campone, M.
    Levy, C.
    Jacot, W.
    Lorgis, V.
    Veyret, C.
    Dalenc, F.
    Ferrero, J. M.
    Uwer, L.
    Kerbrat, P.
    Goncalves, A.
    Mouret-Reynier, M. A.
    Petit, T.
    Jouannaud, C.
    Vanlemmens, L.
    Chenuc, G.
    Guesmia, T.
    Robain, M.
    Cailliot, C.
    ANNALS OF ONCOLOGY, 2016, 27 (09) : 1725 - 1732
  • [6] Phase II study of pembrolizumab and nab-paclitaxel in HER2-negative metastatic breast cancer: Hormone receptor-positive cohort
    Novik, Y.
    Klar, N.
    Zamora, S.
    Kwa, M.
    Speyer, J.
    Oratz, R.
    Muggia, F.
    Meyers, M.
    Hochman, T.
    Goldberg, J.
    Adams, S.
    ANNALS OF ONCOLOGY, 2020, 31 : S59 - S59
  • [7] Phase Ib study of rebastinib plus antitubulin therapy with paclitaxel (P) or eribulin (E) in patients with HER2-negative metastatic breast cancer (MBC)
    Anampa, J. D.
    Xue, X.
    Oh, S-y
    Kornblum, N.
    Sadan, S.
    Oktay, M. H.
    Condeelis, J.
    Sparano, J. A.
    CANCER RESEARCH, 2019, 79 (04)
  • [8] Treatment of HER2-negative metastatic breast cancer (MBC) with bevacizumab (BEV) plus paclitaxel (TXL): A singlecenter phase II study
    Inno, A.
    Strippoli, A.
    Nazzicone, G.
    Quaranta, A.
    Di Salvatore, M.
    Galiano, A.
    Bagala, C.
    Basso, M.
    Pozzo, C.
    Cassano, A.
    Astone, A.
    Barone, C.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [9] Advances in chemotherapy for HER2-negative metastatic breast cancer
    Mukai, Hirofumi
    Ito, Mayuko
    CHINESE CLINICAL ONCOLOGY, 2018, 7 (03)
  • [10] Predictive markers for efficacy of everolimus plus exemestane in patients with luminal HER2-negative metastatic breast cancer
    Okazaki, Misato
    Horimoto, Yoshiya
    Tanabe, Masahiko
    Ichikawa, Yuko
    Tokuda, Emi
    Arakawa, Atsushi
    Kobayashi, Toshiyuki
    Saito, Mitsue
    MEDICAL ONCOLOGY, 2018, 35 (04)
12345